Holen Sie sich die Stockscreener-App
11.40
0.70%
-0.08
Handel nachbörslich:
11.40
Schlusskurs vom Vortag:
$11.48
Offen:
$11.48
24-Stunden-Volumen:
131.56K
Relative Volume:
0.82
Marktkapitalisierung:
$566.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-8.0822
EPS:
-1.4105
Netto-Cashflow:
$-97.30M
1W Leistung:
-23.59%
1M Leistung:
-20.83%
6M Leistung:
-12.31%
1J Leistung:
+66.91%
1-Tages-Spanne:
$11.34
$11.80
1-Wochen-Bereich:
$11.34
$14.73
52-Wochen-Spanne:
$5.85
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Vergleichen Sie MLYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| MLYS | 11.40 | 566.88M | 0 | -119.67M | -97.30M | -1.4105 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat
(MLYS) Trading Signals - Stock Traders Daily
Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MyChesCo
MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews
Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance
Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MyChesCo
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo
Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat
Mineralys Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan
Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com
Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Objective long/short (MLYS) Report - Stock Traders Daily
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks
Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo
When the Price of (MLYS) Talks, People Listen - Stock Traders Daily
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times
Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com
Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com
Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com
Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
(MLYS) Trading Report - Stock Traders Daily
Mineralys Therapeutics to Unveil First Quarter Financial Results - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - cnhinews.com
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):